Diabetes mellitus is a global health issue with numerous complications, and SGLT-2 inhibitors can slow kidney disease progression, reduce heart failure, and lower the risk of kidney failure and death in individuals with CKD. This study evaluated the impact of Sodium-glucose co-transporter 2 (SGLT2) inhibitors, specifically dapagliflozin and empagliflozin, on cardiovascular and renal health in Type 2 Diabetes Mellitus (T2DM) patients at Benghazi Diabetes Center (BDC). The study involved 600 T2DM patients initiating dapagliflozin or empagliflozin, and collected data from interviews, structured questionnaires, and electronic medical records. After three months of treatment, the analysis showed significant improvements in glycemic control, weight management, blood pressure, and lipid profiles, reduced albuminuria, and improved estimated glomerular filtration rate (eGFR) and ejection fraction (EF). However, drug- and sex-specific nuances were revealed. Dapagliflozin showed numerically greater improvements in BP, postprandial glucose, lipid parameters, plasma urea, and albuminuria, while empagliflozin demonstrated numerically greater reductions in weight, body mass index, fasting plasma glucose, and eGFR. Females showed greater reductions in PPG, weight, BMI, BP, and plasma urea, while males demonstrated more pronounced improvements in FPG, triglycerides, low-density lipoprotein cholesterol, albuminuria, and EF. Combined SGLT2 inhibitor use with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers did not show statistically significant differences in clinical parameters compared to SGLT2 inhibitor monotherapy. SGLT2 inhibitors show beneficial effects on cardiorenal and metabolic parameters in T2DM patients, with variations based on drug and sex, emphasizing personalized treatment plans and urging further research.